Form 4: Madrigal Pharmaceuticals Director Jacqualyn A. Fouse Reports Stock and Option Grants
SEC Form 4 Filing
Director Jacqualyn A. Fouse reports the acquisition of restricted stock units and stock options in Madrigal Pharmaceuticals.
Summary
- On March 10, 2025, Jacqualyn A. Fouse, a director of Madrigal Pharmaceuticals, acquired 894 shares of common stock through a grant of restricted stock units.
- These restricted stock units vest in two equal installments on March 10, 2026, and March 10, 2027, contingent upon continued service with the issuer.
- Fouse also acquired options to purchase 1,579 shares of common stock at an exercise price of $329.16.
- These options vest with 50% vesting on March 10, 2026, and the remaining 50% vesting in equal quarterly installments over the following year, also contingent upon continued service.
Sentiment
Score: 7
Explanation: The document reflects standard executive compensation practices, which is generally viewed neutrally to positively as it aligns management interests with shareholders.
Positives
- The grant of restricted stock units and stock options to a director aligns their interests with those of the shareholders, incentivizing them to work towards the company's long-term success.
Future Outlook
The vesting schedules for the restricted stock units and stock options are contingent upon the reporting person's continued service with the issuer.
Industry Context
Stock and option grants are a common form of executive compensation in the pharmaceutical industry, used to attract and retain talent and align management's interests with those of shareholders.
Stakeholder Impact
- The stock and option grants could have a positive impact on shareholders by incentivizing the director to work towards increasing the company's value.
Key Dates
| Date | Description |
|---|---|
| 03/10/2025 | Date of transaction: grant of restricted stock units and stock options. |
| 03/10/2026 | First vesting date for 50% of the restricted stock units and stock options. |
| 03/10/2027 | Second vesting date for the remaining 50% of the restricted stock units. |
| 03/10/2035 | Expiration date of the stock options. |
| 03/12/2025 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.